B-intervention	0	10	Raloxifene
O	11	19	Prevents
B-condition	20	25	Early
I-condition	26	40	Periprosthetic
I-condition	41	45	Bone
I-condition	46	50	Loss
O	51	54	for
B-eligibility	55	69	Postmenopausal
I-eligibility	70	75	Women
I-eligibility	76	81	after
I-eligibility	82	92	Uncemented
I-eligibility	93	98	Total
I-eligibility	99	102	Hip
I-eligibility	103	115	Arthroplasty
O	115	116	:
O	117	118	A
O	119	129	Randomized
O	130	137	Placebo
O	137	138	-
O	138	148	Controlled
O	149	157	Clinical
O	158	163	Trial
O	163	164	.

O	165	167	To
O	168	175	examine
O	176	179	the
O	180	187	results
O	188	190	of
O	191	201	raloxifene
O	202	205	for
O	206	216	prevention
O	217	219	of
O	220	234	periprosthetic
O	235	239	bone
O	240	244	loss
O	245	251	around
O	252	255	the
O	256	263	femoral
O	264	268	stem
O	269	271	in
O	272	280	patients
O	281	291	undergoing
O	292	297	total
O	298	301	hip
O	302	314	arthroplasty
O	315	316	(
O	316	319	THA
O	319	320	)
O	320	321	.

O	322	329	Between
O	330	337	January
O	338	342	2015
O	343	346	and
O	347	350	May
O	351	355	2017
O	355	356	,
B-total-participants	357	360	240
O	361	367	female
O	368	376	patients
B-age	377	384	between
I-age	385	387	55
I-age	388	391	and
I-age	392	394	80
I-age	395	400	years
O	401	410	underwent
O	411	418	primary
O	419	422	THA
O	423	426	and
O	427	431	were
O	432	440	randomly
O	441	450	allocated
O	451	453	to
O	454	461	receive
O	462	464	60
O	465	467	mg
O	468	478	raloxifene
O	479	492	hydrochloride
O	493	496	per
O	497	500	day
O	501	502	(
O	502	511	treatment
O	512	517	group
O	517	518	,
O	519	521	TG
O	521	522	,
O	523	524	n
O	525	526	=
B-intervention-participants	527	530	120
O	530	531	)
O	532	534	or
B-control	535	542	placebo
O	543	544	(
O	544	551	control
O	552	557	group
O	557	558	,
O	559	561	CG
O	561	562	,
O	563	564	n
O	565	566	=
B-control-participants	567	570	120
O	570	571	)
O	572	578	orally
O	579	581	at
O	582	589	bedtime
O	590	595	using
O	596	604	computer
O	604	605	-
O	605	614	generated
O	615	628	randomization
O	629	637	sequence
O	638	648	generation
O	648	649	.

O	650	658	Baseline
O	659	663	data
O	663	664	,
O	665	668	the
O	669	676	Western
O	677	684	Ontario
O	685	693	McMaster
O	694	706	Universities
O	707	721	Osteoarthritis
O	722	727	Index
O	728	729	(
O	729	734	WOMAC
O	734	735	)
O	735	736	,
O	737	742	women
O	742	743	'
O	743	744	s
O	745	752	quality
O	753	755	of
O	756	760	life
O	761	762	(
O	762	765	QoL
O	765	766	)
O	767	772	score
O	772	773	,
O	774	778	bone
O	779	786	mineral
O	787	794	density
O	795	796	(
O	796	799	BMD
O	799	800	)
O	801	807	around
O	808	811	the
O	812	822	prosthesis
O	822	823	,
O	824	827	and
O	828	835	adverse
O	836	842	events
O	843	847	were
O	848	856	compared
O	857	864	between
O	865	868	the
O	869	872	two
O	873	879	groups
O	879	880	.

O	881	884	The
O	885	894	measuring
O	895	900	range
O	901	903	of
O	904	907	BMD
O	908	914	around
O	915	918	the
O	919	929	prosthesis
O	930	933	was
O	934	941	divided
O	942	946	into
O	947	952	seven
O	953	960	regions
O	961	963	of
O	964	972	interest
O	973	974	(
O	974	977	ROI
O	977	978	)
O	978	979	.

O	980	983	The
O	984	990	sample
O	991	995	size
O	996	999	was
O	1000	1010	calculated
O	1011	1013	to
O	1014	1020	detect
O	1021	1022	a
O	1023	1027	mean
O	1028	1038	difference
O	1039	1041	in
O	1042	1045	BMD
O	1046	1048	of
O	1049	1050	0
O	1050	1051	.
O	1051	1053	15
O	1054	1055	g
O	1055	1056	/
O	1056	1059	cm2
O	1060	1064	with
O	1065	1066	a
O	1067	1075	standard
O	1076	1085	deviation
O	1086	1087	(
O	1087	1089	SD
O	1089	1090	)
O	1091	1093	of
O	1094	1095	0
O	1095	1096	.
O	1096	1097	3
O	1097	1098	.

O	1099	1102	The
O	1103	1108	error
O	1109	1112	was
O	1113	1116	set
O	1117	1119	at
O	1120	1121	0
O	1121	1122	.
O	1122	1124	05
O	1125	1128	and
O	1129	1132	the
O	1133	1138	power
O	1139	1144	level
O	1145	1147	at
O	1148	1150	90
O	1150	1151	%
O	1152	1156	with
O	1157	1167	additional
O	1168	1180	compensation
O	1181	1184	for
O	1185	1186	a
O	1187	1195	possible
O	1196	1203	dropout
O	1204	1208	rate
O	1209	1211	of
O	1212	1214	20
O	1214	1215	%
O	1215	1216	.

O	1217	1218	A
O	1219	1224	total
O	1225	1227	of
B-total-participants	1228	1231	240
O	1232	1244	participants
O	1245	1247	in
O	1248	1251	the
O	1252	1257	study
O	1258	1260	up
O	1261	1263	to
O	1264	1266	24
O	1267	1273	months
O	1274	1279	after
O	1280	1283	THA
O	1283	1284	.

O	1285	1290	There
O	1291	1295	were
O	1296	1298	no
O	1299	1310	significant
O	1311	1322	differences
O	1323	1325	in
O	1326	1329	the
O	1330	1334	mean
O	1335	1338	BMD
O	1339	1341	of
O	1342	1345	all
O	1346	1349	the
O	1350	1355	zones
O	1356	1363	between
O	1364	1370	groups
O	1371	1377	before
O	1378	1385	surgery
O	1386	1387	(
O	1387	1390	all
O	1391	1392	P
O	1393	1394	>
O	1395	1396	0
O	1396	1397	.
O	1397	1399	05
O	1399	1400	)
O	1400	1401	.

O	1402	1409	However
O	1409	1410	,
O	1411	1416	there
O	1417	1421	were
O	1422	1433	significant
O	1434	1445	differences
O	1446	1448	in
O	1449	1452	the
B-outcome	1453	1456	BMD
I-outcome	1457	1459	of
I-outcome	1460	1465	Gruen
I-outcome	1466	1471	zones
I-outcome	1472	1473	4
I-outcome	1474	1477	and
I-outcome	1478	1479	7
O	1480	1487	between
O	1488	1494	groups
O	1495	1497	at
O	1498	1499	6
O	1500	1506	months
O	1507	1522	postoperatively
O	1523	1524	(
O	1524	1528	both
O	1529	1530	P
O	1531	1532	<
O	1533	1534	0
O	1534	1535	.
O	1535	1537	05
O	1537	1538	)
O	1538	1539	;
O	1540	1545	there
O	1546	1550	were
O	1551	1562	significant
O	1563	1574	differences
O	1575	1577	in
O	1578	1583	Gruen
O	1584	1589	zones
B-outcome	1590	1591	1
I-outcome	1591	1592	,
I-outcome	1593	1594	4
I-outcome	1594	1595	,
I-outcome	1596	1597	6
I-outcome	1597	1598	,
I-outcome	1599	1602	and
I-outcome	1603	1604	7
I-outcome	1605	1607	at
I-outcome	1608	1610	12
I-outcome	1611	1617	months
I-outcome	1618	1633	postoperatively
O	1634	1635	(
O	1635	1638	all
O	1639	1640	P
O	1641	1642	<
O	1643	1644	0
O	1644	1645	.
O	1645	1647	01
O	1647	1648	)
O	1648	1649	;
O	1650	1655	there
O	1656	1660	were
O	1661	1672	significant
O	1673	1684	differences
O	1685	1687	in
O	1688	1693	Gruen
O	1694	1699	zones
B-outcome	1700	1701	1
I-outcome	1701	1702	,
I-outcome	1703	1704	2
I-outcome	1704	1705	,
I-outcome	1706	1707	4
I-outcome	1707	1708	,
I-outcome	1709	1710	6
I-outcome	1710	1711	,
I-outcome	1712	1715	and
I-outcome	1716	1717	7
I-outcome	1718	1720	at
I-outcome	1721	1723	24
I-outcome	1724	1730	months
I-outcome	1731	1746	postoperatively
O	1747	1748	(
O	1748	1751	all
O	1752	1753	P
O	1754	1755	<
O	1756	1757	0
O	1757	1758	.
O	1758	1761	001
O	1761	1762	)
O	1762	1763	.

O	1764	1772	Patients
O	1773	1779	taking
O	1780	1790	raloxifene
O	1791	1799	reported
O	1800	1806	higher
B-outcome	1807	1810	QoL
I-outcome	1811	1817	scores
O	1817	1818	,
O	1819	1823	with
O	1824	1830	better
O	1831	1842	improvement
O	1843	1845	in
O	1846	1849	BMD
O	1850	1852	in
O	1853	1856	all
O	1857	1862	areas
O	1863	1869	except
O	1870	1872	in
O	1873	1878	zones
O	1879	1880	3
O	1881	1884	and
O	1885	1886	5
O	1887	1895	compared
O	1896	1900	with
O	1901	1904	the
O	1905	1912	control
O	1913	1918	group
O	1918	1919	.

O	1920	1925	There
O	1926	1930	were
O	1931	1933	no
O	1934	1945	significant
O	1946	1957	differences
O	1958	1960	in
B-outcome	1961	1966	WOMAC
I-outcome	1967	1971	pain
O	1972	1973	(
O	1973	1974	P
O	1975	1976	=
O	1977	1978	0
O	1978	1979	.
O	1979	1983	4045
O	1983	1984	)
O	1984	1985	,
B-outcome	1986	1991	WOMAC
I-outcome	1992	2000	function
O	2001	2002	(
O	2002	2003	P
O	2004	2005	=
O	2006	2007	0
O	2007	2008	.
O	2008	2012	4456
O	2012	2013	)
O	2014	2017	and
B-outcome	2018	2023	women
I-outcome	2023	2024	'
I-outcome	2024	2025	s
I-outcome	2026	2029	QoL
I-outcome	2030	2036	scores
O	2037	2038	(
O	2038	2039	P
O	2040	2041	=
O	2042	2043	0
O	2043	2044	.
O	2044	2048	5983
O	2048	2049	)
O	2050	2057	between
O	2058	2064	groups
O	2065	2071	before
O	2072	2079	surgery
O	2079	2080	.

O	2081	2088	However
O	2088	2089	,
O	2090	2095	WOMAC
O	2096	2100	pain
O	2100	2101	,
O	2102	2107	WOMAC
O	2108	2116	function
O	2117	2120	and
O	2121	2126	women
O	2126	2127	'
O	2127	2128	s
O	2129	2132	QoL
O	2133	2138	score
O	2139	2141	in
O	2142	2145	the
O	2146	2155	treatment
O	2156	2161	group
O	2162	2166	were
O	2167	2180	significantly
O	2181	2187	better
O	2188	2190	at
O	2191	2194	all
O	2195	2199	time
O	2200	2206	points
O	2207	2208	(
O	2208	2211	all
O	2212	2213	P
O	2214	2215	<
O	2216	2217	0
O	2217	2218	.
O	2218	2220	05
O	2220	2221	)
O	2221	2222	.

O	2223	2231	Patients
O	2232	2234	in
O	2235	2238	the
O	2239	2248	treatment
O	2249	2254	group
O	2255	2261	showed
O	2262	2264	no
O	2265	2274	increased
O	2275	2282	adverse
O	2283	2289	events
O	2289	2290	,
O	2291	2300	including
O	2301	2308	cardiac
O	2309	2315	events
O	2315	2316	,
O	2317	2323	stroke
O	2323	2324	,
O	2325	2331	venous
O	2332	2347	thromboembolism
O	2347	2348	,
O	2349	2352	and
O	2353	2366	gynecological
O	2367	2373	cancer
O	2374	2375	(
O	2375	2378	all
O	2379	2380	P
O	2381	2382	>
O	2383	2384	0
O	2384	2385	.
O	2385	2387	05
O	2387	2388	)
O	2388	2389	,
O	2390	2393	but
O	2394	2397	did
O	2398	2402	show
O	2403	2412	decreased
O	2413	2417	odds
O	2418	2420	of
O	2421	2427	breast
O	2428	2434	cancer
O	2435	2437	in
O	2438	2448	comparison
O	2449	2453	with
O	2454	2459	those
O	2460	2465	using
O	2466	2467	a
O	2468	2475	placebo
O	2476	2477	(
O	2477	2478	P
O	2479	2480	=
O	2481	2482	0
O	2482	2483	.
O	2483	2487	0437
O	2487	2488	)
O	2488	2489	.

O	2490	2500	Raloxifene
O	2501	2504	can
O	2505	2509	help
O	2510	2517	inhibit
O	2518	2522	bone
O	2523	2527	loss
O	2528	2534	around
O	2535	2538	the
O	2539	2549	prosthesis
O	2550	2553	and
O	2554	2561	improve
O	2562	2565	the
O	2566	2569	QoL
O	2570	2572	of
O	2573	2587	postmenopausal
O	2588	2593	women
O	2594	2599	after
O	2600	2603	THA
O	2604	2608	with
O	2609	2611	no
O	2612	2621	increased
O	2622	2629	adverse
O	2630	2636	events
O	2636	2637	,
O	2638	2641	and
O	2642	2645	can
O	2646	2650	even
O	2651	2659	decrease
O	2660	2663	the
O	2664	2668	odds
O	2669	2671	of
O	2672	2678	breast
O	2679	2685	cancer
O	2685	2686	.
